CR20150502A - Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización - Google Patents
Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilizaciónInfo
- Publication number
- CR20150502A CR20150502A CR20150502A CR20150502A CR20150502A CR 20150502 A CR20150502 A CR 20150502A CR 20150502 A CR20150502 A CR 20150502A CR 20150502 A CR20150502 A CR 20150502A CR 20150502 A CR20150502 A CR 20150502A
- Authority
- CR
- Costa Rica
- Prior art keywords
- antibodies
- specific
- fap
- methods
- biespectific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
La presente invención se refiere a anticuerpos biespecíficos que comprenden por lo menos un sitio de unión a antígeno específico para DR5 y por lo menos un sitio de unión a antígeno específico para FAP, a anticuerpos específicos para DR5, a métodos para la producción de los mismos, a composiciones farmacéuticas que contienen dichos anticuerpos y a usos de los mismos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361808128P | 2013-04-03 | 2013-04-03 | |
PCT/EP2014/056511 WO2014161845A1 (en) | 2013-04-03 | 2014-04-01 | Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20150502A true CR20150502A (es) | 2015-11-19 |
Family
ID=50397172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20150502A CR20150502A (es) | 2013-04-03 | 2015-09-21 | Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización |
Country Status (26)
Country | Link |
---|---|
US (2) | US9926379B2 (es) |
EP (1) | EP2981552B1 (es) |
JP (2) | JP6316937B2 (es) |
KR (2) | KR20170091179A (es) |
CN (1) | CN105308069B (es) |
AR (1) | AR095980A1 (es) |
AU (1) | AU2014247175B2 (es) |
BR (1) | BR112015025306A2 (es) |
CA (1) | CA2903595C (es) |
CL (2) | CL2015002829A1 (es) |
CR (1) | CR20150502A (es) |
EA (1) | EA201500995A1 (es) |
ES (1) | ES2720433T3 (es) |
HK (1) | HK1214604A1 (es) |
IL (1) | IL241795B (es) |
MA (1) | MA38554A3 (es) |
MX (1) | MX370651B (es) |
PE (1) | PE20160506A1 (es) |
PH (1) | PH12015502293A1 (es) |
PL (1) | PL2981552T3 (es) |
SG (1) | SG11201508220UA (es) |
TR (1) | TR201905458T4 (es) |
TW (1) | TWI535736B (es) |
UA (1) | UA118028C2 (es) |
WO (1) | WO2014161845A1 (es) |
ZA (1) | ZA201506471B (es) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
CA2757931C (en) | 2009-04-07 | 2019-03-26 | Roche Glycart Ag | Trivalent, bispecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
JP5695059B2 (ja) | 2009-09-29 | 2015-04-01 | ロシュ グリクアート アーゲー | 二重特異性デス受容体アゴニスト抗体 |
PT2603530T (pt) | 2010-08-13 | 2018-01-09 | Roche Glycart Ag | Anticorpos anti-fap e métodos de utilização |
WO2012025530A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
SI3489255T1 (sl) | 2011-02-10 | 2021-11-30 | Roche Glycart Ag | Mutantni polipeptidi interlevkina-2 |
JP5764677B2 (ja) | 2011-02-28 | 2015-08-19 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 抗原結合タンパク質 |
CA2824824A1 (en) | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Monovalent antigen binding proteins |
EP2747781B1 (en) | 2011-08-23 | 2017-11-15 | Roche Glycart AG | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
CA2871880A1 (en) | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof |
RU2015100656A (ru) | 2012-06-27 | 2016-08-20 | Ф. Хоффманн-Ля Рош Аг | Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения |
KR20150130349A (ko) * | 2013-03-15 | 2015-11-23 | 메르크 파텐트 게엠베하 | 4가 이중특이적 항체 |
UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
KR20160044060A (ko) | 2013-10-11 | 2016-04-22 | 에프. 호프만-라 로슈 아게 | 다중특이적 도메인 교환된 통상의 가변 경쇄 항체 |
JP6706578B2 (ja) * | 2013-12-30 | 2020-06-10 | エピムアブ バイオセラピューティクス インコーポレイテッド | タンデム型Fab免疫グロブリン及びその使用 |
CA2946669A1 (en) * | 2014-05-02 | 2015-11-05 | Medimmune Limited | Ion channel modulators & uses thereof |
EP3204412B1 (en) * | 2014-10-08 | 2020-08-19 | F.Hoffmann-La Roche Ag | Combination therapy of bispecific antibodies specific for fap and dr5 and chemotherapeutic agents |
MX2017006250A (es) | 2014-11-14 | 2017-11-17 | Hoffmann La Roche | Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf. |
MY184889A (en) * | 2014-11-20 | 2021-04-29 | Hoffmann La Roche | T cell activating bispecific antigen binding molecules |
EP4141032A1 (en) | 2014-11-20 | 2023-03-01 | F. Hoffmann-La Roche AG | Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists |
PL3227332T3 (pl) | 2014-12-03 | 2020-06-15 | F. Hoffmann-La Roche Ag | Wielospecyficzne przeciwciała |
EP3234598B1 (en) * | 2014-12-18 | 2019-11-06 | F.Hoffmann-La Roche Ag | Assay and method for determining cdc eliciting antibodies |
EP3242683A1 (en) * | 2015-01-09 | 2017-11-15 | Mabimmune Diagnostics AG | Novel anti-fibroblast activation protein (fap) antibodies and uses derived thereof |
CN107207601A (zh) | 2015-01-20 | 2017-09-26 | Igm生物科学股份有限公司 | 肿瘤坏死因子(tnf)超家族受体结合分子及其应用 |
RU2017129236A (ru) | 2015-01-26 | 2019-03-07 | Макродженикс, Инк. | Мультивалентные молекулы, содержащие dr5-связывающие домены |
EP3277305B1 (en) | 2015-03-31 | 2021-07-21 | F. Hoffmann-La Roche AG | Antigen binding molecules comprising a trimeric tnf family ligand |
TWI721976B (zh) | 2015-04-16 | 2021-03-21 | 美商艾爾德生物製藥股份有限公司 | 抗pacap抗體及其用途 |
EP3112381A1 (en) | 2015-07-01 | 2017-01-04 | FONDAZIONE IRCCS Istituto Nazionale dei Tumori | Bispecific antibodies for use in cancer immunotherapy |
WO2017028279A1 (en) * | 2015-08-19 | 2017-02-23 | Beijing Cotimes Biotech Company Limited | Trail receptor-binding agents and uses of same |
CN105061604B (zh) * | 2015-08-19 | 2018-03-16 | 河南大学 | sDR5‑Fc融合蛋白突变体及其应用 |
JP7084301B2 (ja) * | 2015-08-21 | 2022-06-14 | エフ.ホフマン-ラ ロシュ アーゲー | 低伝導率洗浄緩衝液を用いたアフィニティークロマトグラフィー精製方法 |
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
CA2992863A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific antibodies specific for a costimulatory tnf receptor |
US20180363000A1 (en) * | 2015-12-14 | 2018-12-20 | The Trustees Of The University Of Pennsylvania | Aav-anti pcsk9 antibody constructs and uses thereof |
CR20180365A (es) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
CN109195993B (zh) | 2016-02-06 | 2022-05-10 | 岸迈生物科技有限公司 | 串联fab免疫球蛋白及其用途 |
DK3433280T3 (da) | 2016-03-22 | 2023-06-19 | Hoffmann La Roche | Protease-aktiverede T-celle-bispecifikke molekyler |
EP3231813A1 (en) * | 2016-03-29 | 2017-10-18 | F. Hoffmann-La Roche AG | Trimeric costimulatory tnf family ligand-containing antigen binding molecules |
KR102444717B1 (ko) | 2016-04-15 | 2022-09-16 | 하. 룬드벡 아크티에셀스카브 | 인간화 항-pacap 항체 및 그의 용도 |
WO2017189959A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
EP3243836A1 (en) * | 2016-05-11 | 2017-11-15 | F. Hoffmann-La Roche AG | C-terminally fused tnf family ligand trimer-containing antigen binding molecules |
TW201806972A (zh) | 2016-05-27 | 2018-03-01 | 美商艾伯維生物醫療股份有限公司 | 雙特異性結合蛋白 |
CN109154600A (zh) * | 2016-06-16 | 2019-01-04 | 豪夫迈·罗氏有限公司 | 用于确定cdc诱导抗体的测定法和方法 |
EP3478321A4 (en) | 2016-06-30 | 2020-04-22 | Oncorus, Inc. | PSEUDOTYPIZED ONCOLYTIC VIRAL ADMINISTRATION OF THERAPEUTIC POLYPEPTIDES |
JP2018035137A (ja) | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag | 新規な抗線維芽細胞活性化タンパク質(fap)結合薬剤およびその使用 |
WO2018044948A1 (en) * | 2016-08-29 | 2018-03-08 | Tiziana Life Sciences Plc | Anti-cd3 antibody formulations |
EP3555627B1 (en) | 2016-12-14 | 2023-11-22 | Purdue Research Foundation | Fibroblast activation protein (fap)-targeted imaging and therapy |
UA126284C2 (uk) * | 2016-12-21 | 2022-09-14 | Сефалон, Інк. | Антитіла, які специфічно зв'язуються з людським il-15, та їхнє застосування |
EP3360898A1 (en) | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer |
MA47200A (fr) * | 2017-01-03 | 2019-11-13 | Hoffmann La Roche | Molécules bispécifiques de liaison à l'antigène comprenant un clone 20h4.9 anti-4-1bb |
MA47215A (fr) | 2017-01-09 | 2019-11-13 | Bioxcel Therapeutics Inc | Procédés prédictifs et diagnostiques pour le cancer de la prostate |
EP3606956A1 (en) * | 2017-04-04 | 2020-02-12 | H. Hoffnabb-La Roche Ag | Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap |
CN108997503B (zh) * | 2017-06-06 | 2021-07-23 | 深圳市中科艾深医药有限公司 | 人sDR5-Fc重组融合蛋白及其作为制备治疗生殖系统炎症的药物中的应用 |
MA50102A (fr) | 2017-11-14 | 2020-07-15 | Univ Virginia Patent Foundation | Compositions et méthodes de fabrication et d'utilisation d'anticorps bispécifiques |
KR102194026B1 (ko) * | 2017-12-15 | 2020-12-22 | 경북대학교 산학협력단 | Trail 수용체에 결합하는 펩타이드 및 이의 용도 |
EP3502140A1 (en) * | 2017-12-21 | 2019-06-26 | F. Hoffmann-La Roche AG | Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules |
US11945839B2 (en) | 2017-12-22 | 2024-04-02 | Hoffmann-La Roche Inc. | Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography |
EP3731850A4 (en) | 2017-12-29 | 2021-12-01 | Oncorus, Inc. | ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES |
BR112021012101A2 (pt) | 2018-12-21 | 2021-09-08 | F. Hoffmann-La Roche Ag | Moléculas de ligação ao antígeno agonístico cd28 biespecífico, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método de produção de uma molécula, composição farmacêutica, uso da molécula e método de inibição do crescimento de células tumorais |
EP3763726A1 (en) | 2019-07-08 | 2021-01-13 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
WO2021005125A1 (en) | 2019-07-08 | 2021-01-14 | 3B Pharmaceuticals Gmbh | Compounds comprising a fibroblast activation protein ligand and use thereof |
KR20220032078A (ko) | 2019-07-08 | 2022-03-15 | 쓰리비 파마슈티컬스 게엠베하 | 섬유모세포 활성화 단백질 리간드를 포함하는 화합물 및 그의 용도 |
WO2021010888A1 (en) * | 2019-07-12 | 2021-01-21 | Lipum Ab | Novel bssl antibodies |
CN110669139A (zh) * | 2019-09-18 | 2020-01-10 | 沣潮医药科技(上海)有限公司 | 二聚体免疫粘附素、药物组合物和用途 |
WO2021168274A1 (en) | 2020-02-21 | 2021-08-26 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
TW202216211A (zh) | 2020-07-01 | 2022-05-01 | 美商希沃爾拜克治療公司 | 抗asgr1抗體共軛物及其用途 |
IL303925A (en) | 2021-01-07 | 2023-08-01 | 3B Pharmaceuticals Gmbh | Compounds comprising a protein ligand for fibroblast activation and its use |
EP4050018A1 (en) | 2021-01-07 | 2022-08-31 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
CN113336851B (zh) * | 2021-06-30 | 2021-12-24 | 徐州医科大学 | 新型全人源抗人b7h3抗体、包含所述抗体的组合物及其应用 |
WO2024083021A1 (zh) * | 2022-10-20 | 2024-04-25 | 北京三诺佳邑生物技术有限责任公司 | 特异性结合TRAIL或FasL的抗体组合以及双特异性抗体 |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1096187A (en) | 1977-04-18 | 1981-02-24 | Souhei Monden | Ornament adapted to be fixed by permanent magnets |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5580774A (en) | 1989-07-31 | 1996-12-03 | Eli Lilly And Company | Chimeric antibodies directed against a human glycoprotein antigen |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
AU2782292A (en) | 1991-09-18 | 1993-04-27 | Sloan-Kettering Institute For Cancer Research | Activated stromal fibroblast-specific antibody, f19 and methods of using the same |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
GB9317423D0 (en) | 1993-08-21 | 1993-10-06 | Imp Cancer Res Tech | Monoclonal antibodies |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
PT994903E (pt) | 1997-06-24 | 2005-10-31 | Genentech Inc | Metodos e composicoes para glicoproteinas galactosiladas |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
BR9813365A (pt) | 1997-12-05 | 2004-06-15 | Scripps Research Inst | Método para produção e humanização de um anticorpo monoclonal de rato |
ATE458007T1 (de) | 1998-04-20 | 2010-03-15 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
EP0953639A1 (en) | 1998-04-30 | 1999-11-03 | Boehringer Ingelheim International GmbH | FAPalpha-specific antibody with improved producibility |
US6455677B1 (en) | 1998-04-30 | 2002-09-24 | Boehringer Ingelheim International Gmbh | FAPα-specific antibody with improved producibility |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP2264166B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
WO2001025454A2 (en) | 1999-10-04 | 2001-04-12 | Medicago Inc. | Method for regulating transcription of foreign genes in the presence of nitrogen |
US7504256B1 (en) | 1999-10-19 | 2009-03-17 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing polypeptide |
EP1268550A2 (en) | 2000-03-17 | 2003-01-02 | Boehringer Ingelheim Pharma KG | Human fap-alpha-specific antibodies |
HUP0300369A2 (hu) | 2000-04-11 | 2003-06-28 | Genentech, Inc. | Többértékű antitestek és alkalmazásuk |
DE10034607A1 (de) | 2000-07-20 | 2002-02-07 | Gundram Jung | Multispezifisches Reagenz zur selektiven Stimulierung von Zelloberflächenrezeptoren |
DE10045591A1 (de) | 2000-09-15 | 2002-04-04 | Klaus Pfizenmaier | Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine) |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
DK2314686T4 (da) | 2000-10-06 | 2023-08-21 | Kyowa Kirin Co Ltd | Celler, der danner antistofsammensætninger |
US20020155109A1 (en) | 2001-04-20 | 2002-10-24 | Lynch David H. | Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2 |
WO2003011878A2 (en) | 2001-08-03 | 2003-02-13 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
WO2003035835A2 (en) | 2001-10-25 | 2003-05-01 | Genentech, Inc. | Glycoprotein compositions |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
EP1502603A4 (en) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | AN ANTIBODY COMPOSITION CONTAINING MEDICAMENT FOR PATIENTS WITH Fc gamma RIIIa POLYMORPHISM |
US7691568B2 (en) | 2002-04-09 | 2010-04-06 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-containing medicament |
US20040132140A1 (en) | 2002-04-09 | 2004-07-08 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
US20040110704A1 (en) | 2002-04-09 | 2004-06-10 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
CA2481656A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cells in which activity of the protein involved in transportation of gdp-fucose is reduced or lost |
AU2003236018A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa |
KR20090046973A (ko) * | 2002-11-27 | 2009-05-11 | 아이알엠 엘엘씨 | 암세포에서 세포자멸사를 유도하기 위한 방법 및 조성물 |
CN103833854B (zh) | 2002-12-16 | 2017-12-12 | 健泰科生物技术公司 | 免疫球蛋白变体及其用途 |
PL224786B1 (pl) | 2003-01-22 | 2017-01-31 | Glycart Biotechnology Ag | Wyizolowany kwas nukleinowy, ssaczy wektor ekspresyjny, komórki gospodarza, fuzja polipeptydowa i sposób jej wytwarzania, sposoby in vitro i ex vivo modyfikowania profilu glikozylacji polipeptydu wytwarzanego przez komórki gospodarza |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
CA2542046A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Fused protein composition |
CA2542125A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase |
SI2380911T1 (en) | 2003-11-05 | 2018-07-31 | Roche Glycart Ag | ANTIGEN-RELATED PATIENTS WITH INCREASED ATTENTION ON THE RECEPTOR FC AND EFFECTORAL FUNCTION |
WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
JP2007530588A (ja) | 2004-03-23 | 2007-11-01 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | レセプターカップリング剤およびその治療用途 |
ES2527292T3 (es) | 2004-03-31 | 2015-01-22 | Genentech, Inc. | Anticuerpos anti-TGF-beta humanizados |
CA2885854C (en) | 2004-04-13 | 2017-02-21 | F. Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
SI1791565T1 (sl) | 2004-09-23 | 2016-08-31 | Genentech, Inc. | Cisteinsko konstruirana protitelesa in konjugati |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
CN101137673B (zh) | 2005-01-05 | 2013-12-04 | 比奥根艾迪克Ma公司 | Cripto结合分子 |
US8029783B2 (en) | 2005-02-02 | 2011-10-04 | Genentech, Inc. | DR5 antibodies and articles of manufacture containing same |
EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
PE20071101A1 (es) | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
EP1806365A1 (en) | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
KR100847010B1 (ko) | 2006-07-05 | 2008-07-17 | 아주대학교산학협력단 | 세포사멸 수용체 5 (dr5)에 특이적으로 결합하는 항체 및이를 포함하는 암 예방 또는 치료용 조성물 |
WO2008027236A2 (en) | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Multispecific antibodies |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
MX350962B (es) | 2008-01-07 | 2017-09-27 | Amgen Inc | Metodo para fabricar moleculas heterodimericas de fragmentos cristalizables de anticuerpo, utilizando efectos electrostaticos de direccion. |
JP5719354B2 (ja) | 2009-05-27 | 2015-05-20 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 三重又は四重特異性抗体 |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
ES2534085T3 (es) | 2009-08-17 | 2015-04-17 | Roche Glycart Ag | Inmunoconjugados dirigidos |
JP5695059B2 (ja) * | 2009-09-29 | 2015-04-01 | ロシュ グリクアート アーゲー | 二重特異性デス受容体アゴニスト抗体 |
US9120855B2 (en) | 2010-02-10 | 2015-09-01 | Novartis Ag | Biologic compounds directed against death receptor 5 |
PT2603530T (pt) * | 2010-08-13 | 2018-01-09 | Roche Glycart Ag | Anticorpos anti-fap e métodos de utilização |
SI3489255T1 (sl) | 2011-02-10 | 2021-11-30 | Roche Glycart Ag | Mutantni polipeptidi interlevkina-2 |
WO2012130831A1 (en) | 2011-03-29 | 2012-10-04 | Roche Glycart Ag | Antibody fc variants |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
MY171038A (en) | 2011-08-23 | 2019-09-23 | Roche Glycart Ag | Bispecific antigen binding molecules |
UA116192C2 (uk) * | 2011-08-23 | 2018-02-26 | Рош Глікарт Аг | Активуюча т-клітини біоспецифічна антигензв'язуюча молекула |
KR20150038012A (ko) | 2012-08-08 | 2015-04-08 | 로슈 글리카트 아게 | 인터루킨-10 융합 단백질 및 그의 용도 |
UA118028C2 (uk) * | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
MX2015014538A (es) | 2013-05-07 | 2016-02-05 | Hoffmann La Roche | Moleculas de union a antigenos trimericas. |
EP3277305B1 (en) | 2015-03-31 | 2021-07-21 | F. Hoffmann-La Roche AG | Antigen binding molecules comprising a trimeric tnf family ligand |
-
2014
- 2014-01-04 UA UAA201510604A patent/UA118028C2/uk unknown
- 2014-04-01 JP JP2016505796A patent/JP6316937B2/ja not_active Expired - Fee Related
- 2014-04-01 AU AU2014247175A patent/AU2014247175B2/en not_active Ceased
- 2014-04-01 PE PE2015002115A patent/PE20160506A1/es unknown
- 2014-04-01 ES ES14714275T patent/ES2720433T3/es active Active
- 2014-04-01 PL PL14714275T patent/PL2981552T3/pl unknown
- 2014-04-01 BR BR112015025306A patent/BR112015025306A2/pt not_active IP Right Cessation
- 2014-04-01 MX MX2015013899A patent/MX370651B/es active IP Right Grant
- 2014-04-01 US US14/231,933 patent/US9926379B2/en active Active
- 2014-04-01 AR ARP140101458A patent/AR095980A1/es unknown
- 2014-04-01 CN CN201480030231.5A patent/CN105308069B/zh not_active Expired - Fee Related
- 2014-04-01 KR KR1020177021210A patent/KR20170091179A/ko not_active Application Discontinuation
- 2014-04-01 EP EP14714275.6A patent/EP2981552B1/en not_active Not-in-force
- 2014-04-01 MA MA38554A patent/MA38554A3/fr unknown
- 2014-04-01 CA CA2903595A patent/CA2903595C/en not_active Expired - Fee Related
- 2014-04-01 TR TR2019/05458T patent/TR201905458T4/tr unknown
- 2014-04-01 WO PCT/EP2014/056511 patent/WO2014161845A1/en active Application Filing
- 2014-04-01 KR KR1020157031505A patent/KR20150139909A/ko active IP Right Grant
- 2014-04-01 EA EA201500995A patent/EA201500995A1/ru unknown
- 2014-04-01 SG SG11201508220UA patent/SG11201508220UA/en unknown
- 2014-04-02 TW TW103112362A patent/TWI535736B/zh not_active IP Right Cessation
-
2015
- 2015-09-03 ZA ZA2015/06471A patent/ZA201506471B/en unknown
- 2015-09-21 CR CR20150502A patent/CR20150502A/es unknown
- 2015-09-21 IL IL241795A patent/IL241795B/en not_active IP Right Cessation
- 2015-09-22 CL CL2015002829A patent/CL2015002829A1/es unknown
- 2015-10-02 PH PH12015502293A patent/PH12015502293A1/en unknown
-
2016
- 2016-03-01 HK HK16102349.6A patent/HK1214604A1/zh unknown
-
2017
- 2017-09-05 CL CL2017002244A patent/CL2017002244A1/es unknown
- 2017-10-02 JP JP2017192900A patent/JP2018046823A/ja active Pending
-
2018
- 2018-03-06 US US15/913,713 patent/US11214622B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20150502A (es) | Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización | |
CL2020001048A1 (es) | Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281) | |
CL2018000422A1 (es) | Diacuerpos monovalentes biespecíficos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos | |
NI201800055A (es) | Anticuerpos que se unen específicamente a pd-1 y sus usos. | |
CO2018003452A2 (es) | Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso | |
CL2018000595A1 (es) | Anticuerpos anti-pd1 y métodos de uso | |
ECSP17081744A (es) | Nuevos derivados hidroxiéster,un proceso para su preparación y composiciones farmacéuticas que los contienen | |
ECSP17040521A (es) | Anticuerpos heterodiméricos que se unen a CD3 y a antígenos tumorales | |
GT201400297A (es) | Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
CL2016002455A1 (es) | Anticuerpos multiespecíficos. | |
CO7081144A2 (es) | Anticuerpos biespecíficos contra tweak humana e il17 humana y usos de los mismos | |
ECSP19050049A (es) | Anticuerpos anti-ox40 y sus usos | |
CO2018003436A2 (es) | Anticuerpos agonistas que se unen específicamente a cd40 humana y métodos de uso | |
CR20160033A (es) | Inhibidores de autotaxina que comprenden un nucleo ciclico de anillo heteroaromático-bencil-amida | |
GT201700131A (es) | Composiciones y métodos para anticuerpos dirigidos a bmp6 | |
ECSP14004976A (es) | Anticuerpos anti-il-36r | |
BR112015006824A2 (pt) | anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico | |
CL2015002562A1 (es) | Anticuerpos e inmunoconjugados anti-b7-h4 | |
CO6551674A2 (es) | Anticuerpos anti-her3 y usos de los mismo | |
EA201401204A1 (ru) | Антитела к il-23p19 | |
EA201491357A1 (ru) | Анти-lrp5 антитела и способы их применения | |
BR112016018313A8 (pt) | Moléculas de ligação multiespecíficas iga | |
DK3390450T3 (da) | Anti-cd28-humaniserede antistoffer formuleret til indgivelse til mennesker | |
UY36292A (es) | Compuestos de tetrahidroquinolina para su uso como inhibidores de bromodominios | |
DOP2016000105A (es) | Anticuerpos anti-ccl17. |